Autologous Hematopoietic Cell Transplantation

This large single-center study looked at outcomes when people with relapsed multiple myeloma received a second autologous hematopoietic cell transplant (autoHCT) either later in their disease course ("delayed") or as a planned salvage treatment. The team reviewed 650 patients treated from 2006–20...

This study confirms that long-term cryopreservation of bone marrow for up to 7.8 years does not negatively impact hematopoietic stem cell viability or engraftment success. Results indicate that early-stage marrow collection can effectively preserve stem cell quality before cumulative damage from chemotherapy or radiation occurs. This research supports the long-term storage of autologous bone marrow as a reliable option for future transplantation.

This phase II randomized trial demonstrates that autologous hematopoietic stem cell transplantation (AHSCT) is significantly more effective than mitoxantrone at reducing MRI-detected disease activity in patients with aggressive multiple sclerosis. Results showed a 79% reduction in new T2 lesions and a significant decrease in relapse rates, supporting the need for larger phase III clinical trials.